12th Biosimilars Congregation 2018

12th Biosimilars Congregation 2018 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems.
KEY SPEAKERS:
Boehringer Ingelheim, Teva Pharmaceuticals, Fresenius Kabi SwissBioSim, Takeda, Wockhardt, Glenmark, Lupin, BPCRCS, GE Healthcare, European Medicines Agency, Bioceros, Danish Generic and Biosimilar Medicines Industry Association (IGL), ValeriusBio, ZRx Outcomes Research , Norwegian Medicines Agency, NICE, Polpharma Biologics, NHS – NIHR Clinical Research Network, Sterne, Kessler, Goldstein & Fox , Generics Bulletin, Frontline Pharma Consulting, Purple Squirrel Economics ,Bristows, Arnold & Porter
KEY THEMES:-
Brexit and Biosimilars, Biosimilar strategies , Current market trends ,Biosimilars in Oncology, Current challenges and opportunities , Payer perspective, Biosimilar Interchangeability, CMC, Preclinical and clinical considerations , Impact of Technology, Gain in-depth knowledge on role of technology transfer , Impact on clinical practice, Production of biosimilar MAbs, Right investments & potentials, Latest developments in regulation ,
WHO SHOULD ATTEND:
People from
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs , Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing.

Join this event which provides an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

Show More